Teva Pharmaceuticals USA, INC.

pharmaceutical company

Based in PA

🤖

AI Overview

With $1.2M in lobbying spend across 15 quarterly filings, Teva Pharmaceuticals USA, INC is a significant lobbying presence. Their lobbying covers 4 issue areas. Active from 2019 to 2022.

$1.2M
Total Spend
4
Years Active
1
Firms Hired
9
Lobbyists Deployed
4
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2019$235K
2020$320K
2021$320K
2022$320K

Issues Lobbied

Lobbying Firms

Lobbyists

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Pharmacy, Medicare/Medicaid, MED

Issues pertaining to pharmaceutical and healthcare markets

H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act

H.R.965/ S.340, CREATES Act

H.R.1503, Orange Book Transparency Act

H.R.1520, Purple Book Continuity Act

H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act

H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act

H.R.2376/ S.1227, Prescription Pricing for the People Act

S.1416, Affordable Prescriptions for Patients Act

S.1895, Lower Health Care Costs Act

H.R. 1499, Protecting Consumer Access to Generic Drugs Act

Administration review of drug pricing policies

S.2543, Prescription Drug Pricing Reduction Act

S.1895, Lower Health Care Costs Act

H.R. 3, Lower Drug Costs Now Act

H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act

H.R.2296, METRIC Act

Administration review of drug pricing policies

S.2543, Prescription Drug Pricing Reduction Act

S.1895, Lower Health Care Costs Act

H.R. 3, Lower Drug Costs Now Act

H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act

H.R.1865, FY2020 Further Consolidated Appropriations Act

Administration review of drug pricing policies

S. 2543, Prescription Drug Pricing Reduction Act

S. 1895, Lower Health Care Costs Act

H.R. 3, Lower Drug Costs Now Act

H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act

H.R. 6201, Families First Coronavirus Response Act

H.R. 748, CARES Act

Review of Administration drug pricing policies

S. 2543, Prescription Drug Pricing Reduction Act

S. 1895, Lower Health Care Costs Act

H.R. 3, Lower Drug Costs Now Act

Coronavirus stimulus legislation

Review of Administration drug pricing policies

S. 2543, Prescription Drug Pricing Reduction Act

S. 1895, Lower Health Care Costs Act

H.R. 3, Lower Drug Costs Now Act

Coronavirus stimulus legislation

Review of Administration drug pricing and telehealth policies

H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act

S. 2543, Prescription Drug Pricing Reduction Act

S. 1895, Lower Health Care Costs Act

H.R. 3, Lower Drug Costs Now Act

H.R. 133, FY2021 Omnibus and COVID Relief and Response Act

Review of Administration drug pricing and telehealth policies

Showing 8 of 11 unique descriptions from filings.

Related Analysis

Related Investigations

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.